MedTrace Logo

Efficacy and Safety Study of HS-10542 for IgA Nephropathy

NCT07474636 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-03-16

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.

Conditions

  • IgAN
  • Immunoglobulin A Nephropathy (IgAN)
  • Glomerular Disease

Interventions

DRUG

Placebo

Placebo, QD

DRUG

HS-10542 High Dose

Drug: HS-10542 High Dose, QD

DRUG

HS-10542 Low Dose

Drug: HS-10542 Low Dose, QD

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2027-12-10
Completion
2028-01-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07474636 on ClinicalTrials.gov